EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis



Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis



Headache 52(1): 57-67



To assess efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treatment of acute migraine in patients using topiramate for migraine prophylaxis. There are limited data from prospective controlled trials demonstrating the benefit of triptans in patients who experience migraine attacks while taking prophylactic medication. This was a worldwide, randomized, placebo-controlled, double-blind, multiple-attack study in adults with a >1-year history of migraine taking a stable dose of topiramate for migraine prophylaxis and experiencing ?2 moderate/severe attacks per month. Participants treated 3 moderate/severe attacks in crossover fashion (2 with rizatriptan 1-mg ODT, 1 with placebo) following random assignment to 1 of 3 treatment sequences. The primary end point was 2-hour pain relief. Two-hour pain relief was significantly greater with rizatriptan compared with placebo (55.% vs 17.4%, P < .1). Response rates also favored rizatriptan for sustained pain relief from 2-24 hours (32.6% vs 11.1%, P < .1), 2-hour pain freedom (36.% vs 6.5%, P < .1), normal functional ability at 2 hours (42.2% vs 12.7%, P < .1), and overall treatment satisfaction at 24 hours (6.8% vs 33.6%, P < .1). Few participants reported adverse experiences (16 [15.8%] with rizatriptan, 3 [3.2%] with placebo); none were serious. Rizatriptan 1-mg ODT was superior to placebo at all pain end points for treatment of acute migraine in patients using topiramate for migraine prophylaxis. Rizatriptan was generally well tolerated in this population. These results are comparable with those from clinical trials in patients not using prophylaxis, suggesting that the use of topiramate does not affect the efficacy or tolerability of rizatriptan for acute migraine treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 036257189

Download citation: RISBibTeXText

PMID: 22078129

DOI: 10.1111/j.1526-4610.2011.02027.x



Related references

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 38(4): 281-287, 1998

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 38(4): 281-287, 1998

Rizatriptan for the acute treatment of migraine and migraine recurrence. Neurology 48(3 SUPPL 2): A68, 1997

Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. Journal of Neurology 254(2): 242-249, 2007

Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database. Headache 51(3): 356-368, 2011

Topiramate prophylaxis and response to triptan treatment for acute migraine. Headache 46(9): 1424-1430, 2006

Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble. Headache 33(8): 432-435, 1993

Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: An open label pilot study. Cephalalgia 22(4): 309-312, 2002

Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. Bmc Neurology 4(): 10-10, 2004

Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 26(7): 871-874, 2006

Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42(8): 796-803, September, 2002

Low-dose topiramate in migraine and transformed migraine prophylaxis. Cephalalgia 23(7): 721, September, 2003

Real-world experience in migraine treatment with rizatriptan from US migraine assessment protocol. Neurology 58(7 Supplement 3): A416, April 9, 2002

Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache 48(2): 226-235, 2007

Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society. Medizinische Monatsschrift für Pharmazeuten 21(2): 30-39, 1998